[Form 4] Myriad Genetics Inc Insider Trading Activity

Rhea-AI Filing Summary

Myriad Genetics insider grant and resulting ownership: Benjamin R. Wheeler, identified as the company's Chief Financial Officer, received a grant of 60,000 time-based restricted stock units (RSUs) on 08/16/2025. The RSUs were granted at a reported price of $0 and represent contingent rights to one share of common stock each. Following the grant, the reporting person beneficially owned 95,210 shares. The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date. The Form 4 filing is dated 08/19/2025 and bears the signature entry by Justin Hunter on behalf of Benjamin R. Wheeler.

Positive

• 60,000 RSU grant ties the CFO's compensation to shareholder value through equity-based incentives
• Multi-year vesting (three equal annual installments) supports executive retention and alignment over time
• Clear disclosure of grant date, vesting schedule, and resultant beneficial ownership (95,210 shares) in Form 4

Negative

• Grant issued at $0 indicates compensation issuance rather than purchase, which will dilute shareholders when RSUs settle
• Form 4 does not disclose any performance conditions tied to the RSUs, only time-based vesting

Insights

Financial Analyst

TL;DR: CFO received 60,000 RSUs that vest over three years, increasing insider alignment but adding future share dilution.

The grant of 60,000 time-based restricted stock units to the Chief Financial Officer is a standard executive compensation action intended to retain and align management with shareholder interests. Each RSU converts to one share upon vesting and the award vests in three equal annual installments starting one year after grant, which creates a multi-year retention schedule. The reported grant price of $0 indicates these are compensation awards rather than open-market purchases. Investors should note the immediate increase in beneficial ownership to 95,210 shares and that eventual settlement of vested RSUs will increase the company’s outstanding shares.

Corporate Governance Expert

TL;DR: Time-based RSUs with multi-year vesting reflect routine governance practice to retain senior executives.

The structure—time-based RSUs vesting in three equal annual installments—aligns with common governance practices to encourage continued service and long-term performance focus. The Form 4 discloses the material terms necessary for shareholders to assess timing and potential dilution. The filing does not disclose any performance-based conditions or accelerated vesting triggers; it only specifies time-based vesting. This is a routine, not atypical, compensation disclosure for an officer-level recipient.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wheeler Benjamin Richard

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/16/2025		A		60,000(1)	A	$0	95,210	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	By: Justin Hunter For: Benjamin R. Wheeler	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Benjamin R. Wheeler report on Form 4 for MYGN?

The Form 4 reports a grant of 60,000 time-based restricted stock units to Benjamin R. Wheeler on 08/16/2025, and shows beneficial ownership of 95,210 shares after the grant.

How do the restricted stock units (RSUs) vest for the MYGN grant?

The RSUs vest in three equal annual installments beginning on the first anniversary of the grant date, per the filing explanation.

What price was reported for the RSU grant on the Form 4?

The transaction price reported for the RSU grant is $0, indicating these were issued as compensation awards.

What is Benjamin R. Wheeler's role at Myriad Genetics as listed on the form?

The Form 4 identifies Benjamin R. Wheeler as the company's Chief Financial Officer.

When was the Form 4 filed and who signed it?

The Form 4 reflects the transaction date 08/16/2025 and the filing entry is dated 08/19/2025, signed by Justin Hunter on behalf of Benjamin R. Wheeler.